Mar 7 |
OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript
|
Mar 7 |
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
|
Mar 7 |
OptiNose reports mixed results; initiates Q1 and FY24 outlook
|
Mar 7 |
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Feb 29 |
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
|
Feb 15 |
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
|
Jan 18 |
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
|
Dec 6 |
Optinose falls as FDA delays label expansion for Xhance product
|
Dec 6 |
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
|